CREBBP is altered in 1.47% of acute myeloid leukemia patients [3].

CREBBP is an inclusion criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain CREBBP status and acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open) [4].

CREBBP is an inclusion criterion in 3 clinical trials for secondary acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain CREBBP status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

CREBBP is altered in 23.09% of non-hodgkin lymphoma patients [3].

CREBBP is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CREBBP is altered in 1.75% of hodgkin lymphoma patients [3].

CREBBP is an inclusion criterion in 2 clinical trials for hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CREBBP is altered in 1.44% of myelodysplastic/myeloproliferative neoplasm patients [3].

CREBBP is an inclusion criterion in 2 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CREBBP is altered in 0.29% of myelodysplastic syndromes patients [3].

CREBBP is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

CREBBP is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

CREBBP is altered in 64.09% of follicular lymphoma patients [3].

CREBBP is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CREBBP is altered in 22.59% of diffuse large B-cell lymphoma patients [3].

CREBBP is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CREBBP is altered in 15.96% of urothelial carcinoma patients [3].

CREBBP is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CREBBP status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CREBBP is altered in 10.0% of juvenile myelomonocytic leukemia patients [3].

CREBBP is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is altered in 2.83% of acute myeloid leukemia with myelodysplasia-related changes patients [3].

CREBBP is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is altered in 1.51% of acute leukemia patients [3].

CREBBP is an inclusion criterion in 1 clinical trial for acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for acute erythroid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute erythroid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for acute megakaryoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and chronic myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CREBBP is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].